Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 15/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30855074 | 1.00 | MALT1 (0.37) | MALT1PIK3CAPIK3R1CCNCCDK8 | |
| SCHEMBL29333891 | 0.91 | MALT1 (0.37) | MALT1PIK3CAPIK3R1CCNCCDK8 | |
| SCHEMBL29333887 | 0.88 | MALT1 (0.39) | MALT1PIK3CAPIK3R1CCNCCDK8 | |
| SCHEMBL29338457 | 0.85 | CCNC (0.33) | CCNCCDK8 | |
| SCHEMBL29333817 | 0.83 | CCNC (0.34) | PIK3CACCNCCDK8 | |
| SCHEMBL30855085 | 0.83 | CCNC (0.36) | PIK3CACCNCCDK8 | |
| SCHEMBL29333811 | 0.83 | CCNC (0.36) | PIK3CACCNCCDK8 | |
| SCHEMBL29333821 | 0.83 | CCNC (0.36) | PIK3CACCNCCDK8 | |
| SCHEMBL31008576 | 0.83 | CCNC (0.34) | PIK3CACCNCCDK8 | |
| SCHEMBL29333450 | 0.83 | CCNC (0.34) | PIK3CACCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | MALT1 4516/4885PIK3CA 3512/4885PIK3R1 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.